Immune Editing in Solid Tumors: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Immune editing is the dynamic process through which the immune system shapes tumor evolution by eliminating susceptible malignant cells, maintaining an equilibrium with residual tumor clones, and ultimately permitting the emergence of variants capable of immune escape. In solid tumors, this process is influenced by tumor mutational burden, antigen presentation, stromal architecture, immunosuppressive cytokines, metabolic competition, and therapeutic selection pressure. The classical framework of elimination, equilibrium, and escape provides a biologic explanation for tumor immunogenicity, intratumoral heterogeneity, metastatic progression, and variable responses to immunotherapy. Clinically, immune editing has direct implications for biomarker interpretation, resistance to immune checkpoint inhibitors, treatment sequencing, and the development of combination therapies. Current evidence supports the use of programmed cell death protein 1 or programmed death ligand 1 blockade, cytotoxic T-lymphocyte-associated antigen 4 inhibition, targeted therapies, radiotherapy, cellular therapies, cancer vaccines, and approaches that modify the tumor microenvironment. However, treatment benefit is limited by primary and acquired resistance, immune-related adverse events, and the complex relationship between immune activation and host tolerance. A mechanistic understanding of immune editing is therefore essential for precision oncology and for designing durable, individualized treatment strategies.

Introduction

Solid tumors are not biologically static lesions but evolving ecosystems composed of malignant cells, immune populations, fibroblasts, endothelial cells, extracellular matrix, and soluble mediators. During oncogenesis, immune surveillance can recognize and destroy cells expressing abnormal proteins, altered major histocompatibility complex molecules, or stress-associated ligands. At the same time, immune pressure acts as a selective force that favors malignant clones with reduced immunogenicity or enhanced resistance to immune attack. This reciprocal interaction is referred to as immune editing.

The concept extends the earlier idea of immune surveillance by recognizing that immunity may have both protective and evolutionary consequences. Elimination suppresses emerging tumors, equilibrium constrains residual disease, and escape permits clinically apparent cancer. These phases may occur sequentially or coexist within different regions of the same tumor. The clinical relevance is substantial because the immune phenotype observed at diagnosis may reflect years of selection rather than the original biology of the neoplasm. Consequently, a tumor with a modest mutation burden can remain highly responsive to immunotherapy if it contains effective antigen presentation and an active T-cell response, whereas a tumor with numerous mutations may remain resistant when immune exclusion or suppressive signaling dominates.

Epidemiology / Disease Burden

Solid tumors account for the majority of global cancer incidence and mortality, including carcinomas of the lung, breast, colorectum, prostate, liver, stomach, pancreas, kidney, and head and neck. The burden is amplified by aging populations, tobacco and alcohol exposure, obesity, chronic inflammation, infectious agents, environmental carcinogens, and disparities in screening and access to treatment. Immune editing contributes to disease burden by enabling malignant clones to persist despite host defenses and by promoting progression toward locally invasive and metastatic disease.

The clinical impact of immune-based therapy varies widely across tumor types. Durable responses are relatively more frequent in melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, mismatch repair-deficient colorectal cancer, and several hematologic malignancies, although solid tumor responses remain heterogeneous. In pancreatic cancer, many sarcomas, glioblastoma, and some microsatellite-stable gastrointestinal cancers, an immunosuppressive or physically inaccessible microenvironment frequently limits efficacy. Population-level outcomes are also shaped by comorbidities, performance status, organ function, prior treatment, and the availability of validated predictive biomarkers.

Pathophysiology

Immune editing begins with elimination, in which innate and adaptive immune mechanisms recognize transformed cells. Natural killer cells detect reduced major histocompatibility complex class I expression and stress ligands, while dendritic cells capture tumor antigens and present them to T lymphocytes. CD8-positive cytotoxic T cells can induce apoptosis through perforin and granzyme pathways or death receptor signaling. CD4-positive T cells provide helper functions, support antigen-specific memory, and modulate macrophage and dendritic-cell activity. Interferon signaling can increase antigen presentation and exert direct antiproliferative effects, although persistent signaling may also promote adaptive resistance and selection of resistant clones.

During equilibrium, immune pressure controls tumor growth without complete eradication. This phase may be prolonged and clinically silent. Genetic instability, epigenetic variation, and microenvironmental heterogeneity generate subclones with differing antigen expression, interferon responsiveness, and susceptibility to cytotoxic lymphocytes. Escape occurs when selected variants lose dominant neoantigens, impair antigen processing, downregulate major histocompatibility complex molecules, activate alternative immune checkpoints, or recruit suppressive cells. Common suppressive populations include regulatory T cells, myeloid-derived suppressor cells, tumor-associated macrophages, and dysfunctional dendritic cells.

The tumor microenvironment further shapes immune editing. Transforming growth factor beta promotes fibrosis, exclusion of effector lymphocytes, and regulatory immune differentiation. Vascular endothelial growth factor can inhibit dendritic-cell maturation and create abnormal vasculature that prevents T-cell trafficking. Hypoxia, extracellular adenosine, lactic acidosis, depleted glucose, and altered amino-acid metabolism impair lymphocyte function. Cancer-associated fibroblasts and dense extracellular matrix may form physical barriers, while chronic antigen exposure drives T-cell exhaustion characterized by reduced proliferative capacity and expression of inhibitory receptors such as PD-1, TIM-3, LAG-3, and TIGIT.

Risk Factors

Factors that increase the probability of immune escape include high genomic instability, defective antigen processing, loss of beta-2 microglobulin, defects in interferon signaling, and constitutive activation of oncogenic pathways such as WNT-beta-catenin, RAS-MAPK, and PI3K-AKT. Chronic inflammation may create a paradoxical environment in which tissue injury and cytokine signaling support malignant growth while promoting immune exhaustion. Obesity, smoking-related inflammation, metabolic disease, immunosuppressive medications, and advanced age can alter systemic immune competence. Prior chemotherapy, radiotherapy, targeted treatment, or checkpoint blockade may impose additional selection pressure and contribute to acquired resistance.

Host factors also affect the outcome of immune editing. Germline variation, human leukocyte antigen composition, gut microbiome diversity, nutritional status, autoimmune disease, and baseline organ function may influence antigen recognition and treatment tolerance. These associations are clinically relevant but rarely sufficient to predict benefit independently. Risk assessment should therefore integrate tumor genomics, pathology, immune contexture, clinical status, and previous therapies rather than relying on a single characteristic.

Clinical Features

Immune editing does not produce a unique clinical syndrome. Its consequences appear as tumor initiation, progression, recurrence, metastatic spread, and variable responses to treatment. Patients may present with localized symptoms caused by mass effect, obstruction, bleeding, pain, or organ dysfunction, or with systemic manifestations such as weight loss, fatigue, fever, and paraneoplastic phenomena. Metastatic disease may involve lymph nodes, liver, lung, bone, brain, or other organs according to the primary tumor and its biologic behavior.

Clinically, immune-edited tumors may display rapid progression despite substantial immune infiltration, reflecting dysfunctional or spatially excluded lymphocytes. Others may show delayed responses, mixed responses, or transient enlargement caused by inflammatory infiltration, a phenomenon that complicates assessment after immunotherapy. Hyperprogression has been reported in selected clinical settings, although its definition and frequency remain debated. Recognition of these patterns is important to avoid premature discontinuation of effective treatment or inappropriate continuation in the presence of true progression and clinical deterioration.

Diagnosis

Diagnosis requires standard histopathologic confirmation and staging, supplemented by molecular and immune characterization when treatment decisions depend on predictive biomarkers. Immunohistochemistry can evaluate PD-L1 expression, mismatch repair proteins, and selected lineage or differentiation markers. Molecular testing may identify microsatellite instability, tumor mutational burden, oncogenic drivers, fusion events, homologous recombination defects, and alterations associated with resistance to immune therapy. These tests should be interpreted in the context of tumor type, assay platform, specimen quality, and treatment indication.

Assessment of the immune microenvironment may include the density, location, and phenotype of CD8-positive T cells, regulatory T cells, macrophages, and dendritic cells. A tumor-inflamed phenotype generally differs therapeutically from an immune-excluded or immune-desert phenotype. Nevertheless, immune profiling remains limited by sampling error, temporal change, intratumoral heterogeneity, and inconsistent thresholds. Radiologic imaging remains central for baseline staging and response assessment, while circulating tumor DNA, peripheral immune signatures, and serial transcriptomic approaches are being investigated as complementary tools. Multidisciplinary review is particularly important when biomarker results are discordant or when atypical response patterns occur.

Treatment & Management

Management should be individualized according to tumor type, stage, molecular profile, performance status, comorbidities, and prior treatment. Surgery remains potentially curative for many localized cancers and may reduce tumor burden before adjuvant systemic therapy. Radiotherapy can provide local control and symptom relief and may increase antigen release, although its immunologic effects depend on dose, fractionation, timing, and the surrounding microenvironment. Chemotherapy may induce immunogenic cell death, but it can also cause lymphodepletion and impair immune recovery.

Immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4 have transformed treatment for multiple advanced solid tumors. Their benefit derives not from nonspecific immune stimulation alone but from restoring or enhancing antitumor T-cell activity that has been restrained by checkpoint signaling. Combination approaches can increase response rates but also increase immune-related toxicity. Targeted therapy may improve immune infiltration in selected oncogene-driven tumors, although some combinations carry substantial risks of hepatotoxicity, pneumonitis, rash, colitis, myocarditis, endocrinopathy, or other organ-specific complications.

Clinical management requires baseline evaluation of autoimmune history, organ function, infection risk, medications, and pre-existing pulmonary, cardiac, hepatic, renal, neurologic, or endocrine disease. New symptoms should prompt consideration of immune-related adverse events, infection, disease progression, and treatment-related complications. Corticosteroids remain standard for many moderate or severe immune toxicities, with organ-specific immunosuppression used when necessary. In appropriate cases, treatment interruption, specialist consultation, and structured monitoring allow toxicity control without permanently compromising oncologic benefit. The risk-benefit assessment should be individualized, especially in patients with active autoimmune disease or those requiring chronic immunosuppression.

Recent Advances / Emerging Therapies

Current research seeks to overcome the major barriers created by immune editing. Personalized neoantigen vaccines and messenger RNA platforms aim to expand T-cell responses against patient-specific mutations. Adoptive cellular therapies, including tumor-infiltrating lymphocytes and engineered T-cell receptor approaches, are being adapted for solid tumors, although antigen heterogeneity, trafficking limitations, on-target off-tumor toxicity, and immune suppression remain significant obstacles. Bispecific antibodies and immune agonists are designed to bring effector cells into closer contact with malignant cells or activate costimulatory pathways.

Combination strategies are being evaluated to remodel the microenvironment. These include checkpoint blockade with antiangiogenic agents, chemotherapy, radiotherapy, epigenetic therapy, cellular metabolism modulators, transforming growth factor beta inhibitors, adenosine pathway inhibitors, and agents targeting myeloid cells or cancer-associated fibroblasts. Oncolytic viruses may promote local inflammation and antigen presentation, while intratumoral therapies seek to convert immunologically cold lesions into inflamed sites. Microbiome-directed interventions and biomarker-guided treatment sequencing are also under active investigation.

Important research priorities include distinguishing exhausted but recoverable T cells from irreversibly dysfunctional populations, identifying mechanisms of hyperprogression, improving the reproducibility of tumor mutational burden and PD-L1 testing, and developing dynamic biomarkers that reflect treatment-induced evolution. Longitudinal sampling, single-cell analysis, spatial transcriptomics, and artificial intelligence-assisted pathology may clarify how immune states vary within and between metastatic sites. Future therapeutic benefit will likely depend on rational combinations rather than indiscriminate escalation of immune activation.

Guideline Recommendations

Contemporary oncology guidelines recommend selecting immunotherapy according to tumor-specific evidence, approved indications, validated biomarkers, disease stage, and patient preference. Molecular testing should be performed when results can identify targeted treatment or establish eligibility for immune checkpoint blockade, including assessment for mismatch repair deficiency or microsatellite instability in relevant cancers. PD-L1 expression may guide therapy in several malignancies, but a negative result does not universally exclude benefit and should not be interpreted outside the validated clinical context.

Guidelines generally support multidisciplinary treatment planning, clinical trial participation, careful documentation of baseline disease, and standardized radiologic follow-up. Clinicians should educate patients about early symptoms of immune-related toxicity and provide clear pathways for urgent evaluation. Suspected immune-mediated adverse events require grading, exclusion of competing diagnoses, and organ-specific management. Rechallenge after toxicity should be considered only after recovery and a careful assessment of recurrence risk. Because recommendations evolve rapidly, clinicians should consult current national and international guidance, regulatory approvals, and disease-specific consensus statements rather than extrapolating evidence across tumor types.

Conclusion

Immune editing is a central principle of solid-tumor biology that links immune surveillance with tumor evolution, therapeutic resistance, and clinical heterogeneity. The stages of elimination, equilibrium, and escape explain why tumors differ in antigenicity, immune infiltration, metastatic potential, and sensitivity to checkpoint inhibition. Effective management requires integration of pathology, molecular testing, immune profiling, imaging, patient factors, and longitudinal assessment. Checkpoint inhibitors and combination therapies have produced durable benefit for selected patients, but toxicity, resistance, and immune exclusion remain major limitations. Future progress will depend on dynamic biomarkers, rationally designed combination regimens, improved understanding of tumor-microenvironment interactions, and treatment strategies that selectively restore antitumor immunity while preserving normal tissue tolerance.